4.8 Article

Au@Prussian Blue Hybrid Nanomaterial Synergy with a Chemotherapeutic Drug for Tumor Diagnosis and Chemodynamic Therapy

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 11, Issue 43, Pages 39493-39502

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.9b13470

Keywords

Fenton reaction; doxorubicin; hydrogen peroxide; hydroxyl radicals; computed tomography imaging; chemo-dynamic therapy

Funding

  1. China Postdoctoral Science Foundation [2018M633141]
  2. National Natural Science Foundation of China (NSFC) [21671137, 51701054, 31870993]
  3. Programs for Science and Technology Development of Shenzhen [JSGG20160328151657828]
  4. Major industrial projects of Shenzhen [s2017001850011]
  5. Fundamental Research Funds for the Central Universities [WK2070000128]

Ask authors/readers for more resources

Recently, the chemodynamic therapy (CDT) has been widely reported and applied to tumor therapy. However, only low level hydroxyl radicals ((OH)-O-center dot) generated by the endogenous hydrogen peroxide alone are insufficient to kill the cancer cells. To overcome the insufficient therapeutic effect, this study reports a novel CDT based on Fenton catalyst Au@Prussian blue nanocubes (Au@PB NCs), subsequently encapsulated with doxorubicin (Dox). The in vitro and in vivo results indicate that the Dox-Au@PB NCs can take synergistic effects on tumor suppressor by CDT. In addition, Au@PB NCs possess high X-ray computed tomography contrast enhanced efficiency about similar to 27.13 HU.mL.mg(-1). This study highlights a great potential of the Dox-Au@PB NCs for tumor diagnosis and CDT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available